Drug companies are minting billions on unproven treatments with FDA shortcut
A shortcut is allowing drugs on the market that haven’t passed through final clinical testing on a Scout’s honor system, but companies are waiting on providing conclusive data – some near decades.
By Robert Langreth, Fiona Rutherford, Immanual John Milton & Madeline Campbell, bloomberg
When Exondys 51 was approved to treat Duchenne muscular dystrophy, a deadly disease that puts kids in wheelchairs by the time they are teenagers, there was no proof the drug actually slowed the disease. That was seven years ago. The company still hasn’t provided conclusive data to this day.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Biogen's Alzheimer's drug loses subsidies in the US
For subscribers
